Results of Annual General Meeting

March 31st, 2022

BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that at its Annual General Meeting, held today at 12.00pm, all resolutions were duly passed.